Method for diagnosing a molecular phenotype of a patient suffering from an illness accompanied by chronic inflammation

A method for diagnosing and treating chronic inflammation in a patient suffering from an illness accompanied by chronic inflammation characterized by a dominance of T-cells of the Th1 subtype with increased expression of Tbet and Interferon gamma and/or increased Interferon gamma release, in combination with a relative absence of Th2-driven inflammatory features such as GATA-3 expression, expression and/or release of IL-4, IL-5 and IL-13 and accumulation of eosinophil granulocytes by identifying a molecular phenotype of the patient wherein the molecular phenotype is selected from the group consisting of the subgroups “Th1 high” and “Th1 low” and the gene expression of GATA-3 and/or Tbet is measured in a biological isolate of the patient and used for the assignment to a molecular phenotype of the illness wherein a therapeutic agent for downregulating Tbet expression is administered when the patient has a molecular phenotype of Th1 high and a therapeutic agent for downregulating the effects of GATA 3 is administered when the patient has a molecular phenotype of Th1 low.